In pre-clinical studies, oral small molecule shown to elevate
HDL-cholesterol levels and reduce LDL-cholesterol and triglyceride levels
ANN ARBOR, Mich., July 24 /PRNewswire-FirstCall/ -- Esperion Therapeutics,
Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the discovery,
development and commercialization of therapies to improve the treatment of
cardiovascular disease, has initiated a Phase I study of ETC-1001, the
Company's lead oral small molecule product candidate. ETC-1001 is intended to
be a chronic treatment for individuals with lipid disorders. The double-
blind, placebo-controlled study will evaluate the safety and tolerability of
single escalating doses of ETC-1001 in up to 36 healthy volunteers.
Esperion's oral small molecule drug discovery program is focused on
identifying and developing new treatments for lipid disorders. Esperion
intends to develop oral small molecules as a chronic therapy to complement
statins and other lipid regulating agents.
ETC-1001 is a synthetic, orally-active lipid regulating agent designed to
elevate levels of high-density lipoprotein cholesterol (HDL-C), the "good"
cholesterol. In pre-clinical studies, ETC-1001 demonstrated the ability to
elevate HDL-cholesterol levels, while also reducing levels of low-density
lipoprotein cholesterol (LDL-C), the "bad" cholesterol, and triglycerides.
ETC-1001 was also shown to inhibit the progression of atherosclerosis in pre-
clinical models.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of high-
density lipoprotein, or HDL, function. HDL is the primary facilitator of the
reverse lipid transport, or RLT, pathway by which excess cholesterol and other
lipids are removed from artery walls and other tissues and are transported to
the liver for elimination from the body. Esperion's goal is to develop drugs
that exploit the beneficial functions of HDL within the RLT pathway. Esperion
currently has product candidates under development for the treatment of
cardiovascular disease. Esperion is listed on the Nasdaq National Market
under the symbol "ESPR."
Safe Harbor Statement
The information contained in this press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are often identified by words such
as "hope," "may," "believe," "anticipate," "plan," "expect," "require,"
"intend," "assume" and similar expressions. Forward-looking statements speak
only as of the date of this press release, reflect management's current
expectations, estimations and projections and involve certain factors, such as
risks and uncertainties, that may cause actual results, performance or
achievements to be far different from those suggested by the Company's
forward-looking statements. These factors include, but are not limited to,
risks associated with: the Company's ability to successfully execute its
business strategies, including entering into any strategic partnerships or
other transactions; the progress and cost of development of the Company's
product candidates; the extent and timing of market acceptance of new products
developed by the Company or its competitors; dependence on third parties to
conduct clinical trials for the Company's product candidates; the extent and
timing of regulatory approval, as desired or required, for the Company's
product candidates; the Company's dependence on licensing arrangements and
strategic relationships with third parties; clinical trials; manufacturing;
the Company's dependence on patents and proprietary rights; the procurement,
maintenance, enforcement and defense of the Company's patents and proprietary
rights; competitive conditions in the industry; business cycles affecting the
markets in which any of the Company's products may be sold; extraordinary
events and transactions; the timing and extent of the Company's financing
needs and the Company's access to funding, including through the equity
market; fluctuations in foreign exchange rates; and economic conditions
generally or in various geographic areas. These factors are discussed in more
detail in the Company's filings with the Securities and Exchange Commission.
The Company does not intend to update any of these factors or to publicly
announce the results of any revisions to any of these forward-looking
statements other than as required under the federal securities laws.
Company Amy Cannon
Contact: Manager, Corporate Communications
Esperion Therapeutics, Inc.
(734) 222-1801
acannon@esperion.com
Media Jim Wetmore
Contact: Berry & Company Public Relations
(212) 253-8881
jwetmore@berrypr.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
CONTACT:
Company Contact: Amy Cannon, Manager,
Corporate Communications of Esperion Therapeutics, Inc.,
+1-734-222-1801, acannon@esperion.com ; or Media Contact: Jim
Wetmore of Berry & Company Public Relations, +1-212-253-8881,
jwetmore@berrypr.com , for Esperion Therapeutics, Inc.
|
